RGNX Share Price Performance
US$9.12
-0.64 (-6.56%)
24.0% undervalued intrinsic discount
US$12.00
Fair Value
Price US$9.12
AnalystLowTarget US$12.00
AnalystConsensusTarget US$29.75
AnalystHighTarget US$51.93
Fair ValueUS$12.00
Share Pricen/a
REGENXBIO Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
RGNX Community Narratives
AN
Fair Value
·Fair Value US$12 24.0% undervalued intrinsic discount
Regulatory Hurdles Will Burden Gene Therapy Yet Sustain Modest Optimism
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$29.75 69.3% undervalued intrinsic discount
Gene Therapy Breakthroughs Will Unlock Expanding Future Markets
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$51.93 82.4% undervalued intrinsic discount
Pipeline Launches And Demographic Trends Will Drive Broad Gene Adoption
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Hurdles Will Burden Gene Therapy Yet Sustain Modest Optimism
Key Takeaways Reliance on a few pivotal programs and regulatory uncertainties could hinder top-line growth and threaten margins if setbacks occur. High R&D costs and funding challenges may force further dilution, with competitive pressures risking both revenue growth and long-term profitability.Read more
AN
US$12
24.0% undervalued intrinsic discount
Fair Value
Profit Margin
12.79%
Future PE
17.58x
Price in 2029
US$15.12
Pipeline Launches And Demographic Trends Will Drive Broad Gene Adoption
Key Takeaways The company's advanced manufacturing and strong pipeline provide significant upside for margin expansion, rapid commercialization, and durable revenue growth beyond analyst expectations. Growing opportunities in personalized medicine and technology out-licensing could drive high-margin, recurring income streams and sustain long-term earnings growth.Read more
AN
US$51.93
82.4% undervalued intrinsic discount
Fair Value
Profit Margin
14.17%
Future PE
45.71x
Price in 2028
US$63.98
Gene Therapy Breakthroughs Will Unlock Expanding Future Markets
Key Takeaways Advancing multiple late-stage gene therapy programs and forming strategic partnerships position REGENXBIO for commercial growth with reduced financial risk. Strong in-house manufacturing and a favorable regulatory outlook enhance scalability, margins, and expedite revenue realization from first-in-class therapies.Read more
AN
US$29.75
69.3% undervalued intrinsic discount
Fair Value
Profit Margin
16.06%
Future PE
30.68x
Price in 2028
US$36.67
Trending Discussion
Recently Updated Narratives
AN
RGNX: Future Gene Therapy Milestones Will Test Regulatory Risk And Support Bullish Reassessment
Fair Value: US$12 24.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pipeline Launches And Demographic Trends Will Drive Broad Gene Adoption
Fair Value: US$51.93 82.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Gene Therapy Breakthroughs Will Unlock Expanding Future Markets
Fair Value: US$29.75 69.3% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
REGENXBIO Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -3.76
- -45.86%
- -113.75%
- 182.0%
About RGNX
- Founded
- 2008
- Employees
- 371
- CEO
- WebsiteView website
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Recent RGNX News & Updates
